Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine

David M Thomas; Stephen Fox; Paula K Lorgelly; David Ashley; Gary Richardson; Lara Lipton; John P Parisot; Mark Lucas; John McNeil; Michael Wright; Cancer 2015 Investigators

doi:10.1016/j.drudis.2015.10.009

Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine

Drug Discov Today. 2015 Dec;20(12):1429-32. doi: 10.1016/j.drudis.2015.10.009. Epub 2015 Oct 19.

Authors

Affiliations

¹ The Kinghorn Cancer Centre and Cancer Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia. Electronic address: d.thomas@garvan.org.au.
² Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Department of Pathology, University of Melbourne, Melbourne, VIC, Australia; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
³ Centre for Health Economics, Monash School of Business, Monash University, Clayton, VIC, Australia.
⁴ Andrew Love Cancer Centre, Barwon Health, School of Medicine, Deakin University, Geelong, VIC, Australia.
⁵ Cabrini Institute, Malvern, Melbourne, VIC, Australia.
⁶ Royal Melbourne Hospital, Parkville, VIC, Australia.
⁷ Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
⁸ School of Public Health & Preventive Medicine, Department of Epidemiology & Preventive Medicine, Monash Faculty of Medicine Nursing & Health Sciences, Alfred Hospital, Prahran,, Melbourne, VIC, Australia.

PMID: 26494144
DOI: 10.1016/j.drudis.2015.10.009

Abstract

Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'whole-of-system' impact of genomic cancer medicine, we have established a prospective cohort of patients with newly diagnosed cancer in the state of Victoria, Australia, about whom we have collected a broad range of clinical, demographic, molecular, and patient-reported data, as well as data on health resource utilization. Our goal is to create a model for investigating public investment in genomic medicine that maximizes the cost:benefit ratio for the Australian community at large.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Australia
Genomics / methods
Humans
Longitudinal Studies
Medicine / methods
Neoplasms / drug therapy*
Neoplasms / genetics*
Precision Medicine / methods
Prospective Studies